Accessibility Menu
Arrow-Thin-Down
S&P 500
6,775.80
-0.1%
-5.68
Arrow-Thin-Down
DJI
47,417.27
-0.6%
-289.24
Arrow-Thin-Down
NASDAQ
22,716.13
+0.1%
+19.03
Arrow-Thin-Down
Bitcoin
$69,389.00
-0.5%
-$332.54
Arrow-Thin-Down
AMZN
$212.65
-0.8%
-$1.68
Arrow-Thin-Down
GOOG
$308.51
+0.5%
+$1.58
Arrow-Thin-Down
META
$654.95
+0.1%
+$0.88
Arrow-Thin-Down
MSFT
$404.73
-0.3%
-$1.03
Arrow-Thin-Down
NVDA
$185.94
+0.6%
+$1.18
Arrow-Thin-Down
TSLA
$407.53
+2.1%
+$8.30
Most Active StocksDaily Stock GainersDaily Stock Losers

2 Ways Orexigen Is Up

A rare positive dilution.

By Dave Williamson – Oct 25, 2012 at 3:44PM EST

In this video, health care analyst David Williamson discusses the recent events around Orexigen Therapeutics, including today's rarely seen price-increasing dilutive offering. Is Orexigen a looming threat to obesity-drug-making heavyweights Arena and VIVUS? Watch and find out. 

Read Next

About the Author

Dave Williamson
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
XMFGreenwave4
X@motleydavid

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services